Therapeutical effects of PPAR agonists assessed by biomarker modulation

被引：7

作者：

Chinetti-Gbaguidi, G

Fruchart, JC

Staels, B

机构：

[1] Inst Pasteur, UR 545 INSERM, F-59019 Lille, France

[2] Univ Lille 2, Lille, France

来源：

BIOMARKERS | 2005年 / 10卷

关键词：

nuclear receptors; fibrates; glitazones; metabolic syndrome;

D O I：

10.1080/13547500500216702

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The metabolic syndrome is defined as the clustering of cardiovascular risk factors, such as glucose intolerance, hyperinsulinemia, dyslipidemia, coagulation disturbances and hypertension. Activators of the nuclear receptors peroxisome proliferator-activated receptors (PPARs) modulate several of the metabolic risk factors pre-disposing to atherosclerosis. Fibrates are hypolipidemic drugs operating through activation of PPAR alpha, whereas glitazones are insulin sensitizers activating PPAR gamma. In addition, these drugs exert pleiotropic and anti-inflammatory actions. This review will focus on the different effects of fibrates and glitazones, as measured by biomarker modulation, on the development of atherosclerosis and cardiovascular disease.

引用

收藏

页码：S30 / S36

页数：7

相关论文

共 34 条

[1] CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors [J].

Chinetti, G ;

Gbaguidi, FG ;

Griglio, S ;

Mallat, Z ;

Antonucci, M ;

Poulain, P ;

Chapman, J ;

Fruchart, JC ;

Tedgui, A ;

Najib-Fruchart, J ;

Staels, B .

CIRCULATION, 2000, 101 (20) :2411-2417

[2] Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications [J].

Chinetti, G ;

Fruchart, JC ;

Staels, B .

INTERNATIONAL JOURNAL OF OBESITY, 2003, 27 (Suppl 3) :S41-S45

[3]

Chinetti G, 2001, Z Kardiol, V90 Suppl 3, P125

[4] PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway [J].

Chinetti, G ;

Lestavel, S ;

Bocher, V ;

Remaley, AT ;

Neve, B ;

Torra, IP ;

Teissier, E ;

Minnich, A ;

Jaye, M ;

Duverger, N ;

Brewer, HB ;

Fruchart, JC ;

Clavey, V ;

Staels, B .

NATURE MEDICINE, 2001, 7 (01) :53-58

[5] Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation [J].

Chinetti, G ;

Fruchart, JC ;

Staels, B .

INFLAMMATION RESEARCH, 2000, 49 (10) :497-505

[6] Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome [J].

Després, JP ;

Lemieux, I ;

Pascot, A ;

Alméras, N ;

Dumont, M ;

Nadeau, A ;

Bergeron, J ;

Prud'homme, D .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (04) :702-703

[7] Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells [J].

Faveeuw, C ;

Fougeray, S ;

Angeli, V ;

Fontaine, J ;

Chinetti, G ;

Gosset, P ;

Delerive, P ;

Maliszewski, C ;

Capron, M ;

Staels, B ;

Moser, M ;

Trottein, F .

FEBS LETTERS, 2000, 486 (03) :261-266

[8] Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-α activator fenofibrate [J].

Gervois, P ;

Kleemann, R ;

Pilon, A ;

Percevault, F ;

Koenig, W ;

Staels, B ;

Kooistra, T .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (16) :16154-16160

[9] Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β [J].

Gervois, P ;

Vu-Dac, N ;

Kleemann, R ;

Kockx, M ;

Dubois, G ;

Laine, B ;

Kosykh, V ;

Fruchart, JC ;

Kooistra, T ;

Staels, B .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (36) :33471-33477

[10]

Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO

← 1 2 3 4 →